论文部分内容阅读
2011年9月23日,美国FDA批准Remicade(infliximab)用于治疗6岁以上儿童对常规治疗反应不佳的中度至严重活动性溃疡性结肠炎(UC)。Remicade可以减轻这些患者的UC症状,并且诱导及延长临床缓解期。UC是一种影响大肠(结肠)和直肠内膜的炎性肠病(IBD)。UC的症状包括腹痛、腹泻、直肠出血、体重减轻和发热。在美国,有50 000～100 000名儿童患有IBD,其中40%为UC。肿瘤坏死因子(TNF)在体内可引起炎症和导致自身免疫病。Remicade为TNF阻滞剂,通过阻断TNF活性来
On September 23, 2011, the U.S. FDA approved Remicade (infliximab) for the treatment of moderate to severe active ulcerative colitis (UC) in children over 6 years old who did not respond well to routine treatment. Remicade can reduce the symptoms of UC in these patients and induce and prolong the clinical remission period. UC is a type of inflammatory bowel disease (IBD) that affects the large intestine (colon) and the rectum. Symptoms of UC include abdominal pain, diarrhea, rectal bleeding, weight loss and fever. In the United States, 50 000 to 100 000 children have IBD, 40% of whom are UC. Tumor necrosis factor (TNF) can cause inflammation in vivo and lead to autoimmune diseases. Remicade is a TNF blocker that blocks TNF activity